{
    "nctId": "NCT05394285",
    "briefTitle": "A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer",
    "officialTitle": "A Single-center, Randomized, Self-controlled Exploratory Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Comparison of response rates to platelet-raising therapy in two chemotherapy cycles",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. The patients signed the informed consent and voluntarily joined the study;\n2. Age 18-75 years old, male or female;\n3. Patients with advanced breast cancer diagnosed by histopathology or cytology, who are receiving and continue to receive the same chemotherapy regimen;\n4. Can accept the current chemotherapy regimen (must be platinum-containing chemotherapy regimen: lobaplatin, carboplatin, cisplatin, etc.) for at least 2 cycles;\n5. The first occurrence of platelets \\<50\u00d7109/L in the current chemotherapy cycle;\n6. The investigator determines that the patient can receive hetrombopag administration;\n7. Neutrophil count \u2265 1.0\u00d7109/L, hemoglobin \u2265 80g/L before administration of Haitrombopag;\n8. Life expectancy at screening \u2265 12 weeks;\n9. ECOG: 0-1;\n10. The main organ functions are normal, and there are no serious complications.\n\nExclusion Criteria:\n\n1. Women who are pregnant or breastfeeding;\n2. Unable to understand the research nature of the research or have not obtained informed consent;\n3. The investigator judges other circumstances that are not suitable for inclusion in the study;\n4. Thrombocytopenia caused by other causes (chronic liver disease, sepsis, disseminated intravascular coagulation, immune thrombocytopenia, etc.);\n5. Patients with unstable angina pectoris, congestive heart failure, uncontrolled hypertension, uncontrolled arrhythmia or recent history (within 1 year of screening) of myocardial infarction;\n6. Those with a history of blood disease or tumor bone marrow infiltration;\n7. Those who received simultaneous radiotherapy and those who received pelvic radiotherapy in the past;\n8. Arterial or venous thrombotic events within the past 6 months;\n9. There are currently uncontrollable infections;\n10. Clinical manifestations of severe bleeding within 2 weeks before screening, such as gastrointestinal or central nervous system bleeding;\n11. Need emergency treatment, such as superior vena cava syndrome, spinal cord compression;\n12. The absolute value of neutrophils is less than 1.0\u00d7109/L, and the hemoglobin is less than 80g/L, and granulocyte colony-stimulating factor, red blood cells, and EPO infusion therapy in accordance with clinical routine are allowed;\n13. Obvious abnormal liver function: patients without liver metastases, ALT/AST\\>3ULN (upper limit of normal value), TBIL\\>3ULN; patients with liver metastases, ALT/AST\u22655ULN, TBIL\u22655ULN;\n14. Abnormal renal function: serum creatinine \u2265 1.5ULN or eGFR \u2264 60 ml/min (Cockcroft-Gault formula);\n\n16. Received thrombopoietin receptor agonist drugs (such as Eltrombopag, Romigrastim), or recombinant human thrombopoietin (rhTPO), recombinant human interleukin-11 (rhIL) within 1 month before screening -11) Treatment; 17. Received platelet transfusion within 3 days before randomization; 18. Patients with known or expected hypersensitivity or intolerance to the active ingredients or excipients of Hetrombopag ethanolamine tablets.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}